A EUFOREA comment on a lost comorbidity of asthma
Research output: Contribution to journal › Letter › Research › peer-review
Documents
- Fulltext
Final published version, 780 KB, PDF document
“Epidemiology of comorbidities and their association with asthma control” (Tomisa, G., Horváth, A., Sánta, B. et al. Epidemiology of comorbidities and their association with asthma control. Allergy Asthma Clin Immunol 17, 95 (2021). https://doi.org/10.1186/s13223-021-00598-3) is an interesting paper reflecting data collection from more than 12,000 asthmatic patients in Hungary regarding their condition and associated comorbidities. We found it valuable that the paper provides an overview of asthma comorbidities not usually considered in similar reports. Nevertheless, we believe that chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP or CRSsNP) should have been listed due to its high incidence and prevalence, its association with asthma which is also endorsed in both GINA and EPOS, as well as in several peer-reviewed scientific papers, and to reflect the role of this comorbidity in poor control and a most severe presentation of asthma for the patient. Consequently, several targeted therapies (especially monoclonal antibodies) used for several years in severe forms of asthma are now indicated also for the effective treatment of nasal polyps.
| Original language | English |
|---|---|
| Article number | 56 |
| Journal | Allergy, Asthma and Clinical Immunology |
| Volume | 19 |
| Issue number | 1 |
| ISSN | 1710-1484 |
| DOIs | |
| Publication status | Published - 2023 |
Bibliographical note
Funding Information:
Diego Conti is the academic manager at EUFOREA. He has no competing interest to declare. Peter Hellings is consultant and recipient of lecture fees and/or research grants from Sanofi, Regeneron, Novartis, GSK, ALK, and Viatris. Zuzana Diamant received in the past three years speaker fees or honoraria or serving on advisory boards or as a consultant from Antabio, Boehringer Ingelheim, Foresee Pharmaceuticals, GlaxoSmithKline, QPS-Netherlands, Sanofi-Genzyme-Regeneron, all outside the submitted work. Leif Bjermer has no competing interest to declare in relation to this work. Milos Jesenak reports receiving consultancy/speaker honoraria from CSL Behring, SOBI, Novartis, GSK, Sanofi, Viatris, and Takeda Pharmaceutical Co. Ltd.; and serving as a principal investigator for clinical trials sponsored by Takeda, Mundipharma, Octapharma, BioCryst Pharmaceuticals, Inc. and Pharming Group NV. Vibeke Backer has no competing interest to declare in relation to this work. Wytske Fokkens has no competing interest to declare in relation to this work. Susanne Lau has received honoraria for lectures and AD Boards from Sanofi-Aventis, DBV, Allergopharma, ALK, Leti, GSK, and Leo Pharma in the last three years. Elizabeth Van Staeyen is the Scientific Communications & Advocacy Manager at EUFOREA. She has no competing interest to declare. Glenis Scadding is a Board member of EUFOREA. She has received remuneration from Sanofi Regeneron and has undertaken trials for GSK.
Publisher Copyright:
© 2023, The Author(s).
- Allergic rhinitis, Asthma, Chronic rhinosinusitis with nasal polyps, Chronic rhinosinusitis without nasal polyps, Comorbidities
Research areas
ID: 369473322